Compare Davita Inc (DVA) vs Ferrari NV (RACE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Davita Inc vs Ferrari NV — how do they compare? Davita Inc trades at $175.04 (market cap $11.29B), while Ferrari NV trades at $390.35 (market cap $67.35B). The key difference: Ferrari NV is far larger — about 6× Davita Inc's market cap, and Ferrari NV pays a 1.09% dividend while Davita Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Davita Inc for 113 Days and Ferrari NV for 126 Days on average.
| DVA | RACE | |
|---|---|---|
Market Cap | $11.29B | $67.35B |
Volume | 582,204 | 390,618 |
Sector | Health | Consumer Cyclical |
52-Week High | $240.96 | $436.54 |
52-Week Low | $103.87 | $314.63 |
Typical Hold Time | 113 Days | 126 Days |
Enterprise Value | $24.01B | $69.22B |
Dividend Yield | — | 1.09% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $176.78, down 2.01% today, showing technical bearish signals with price near key support at $175. Fundamentally, the company demonstrates solid earnings performance with three consecutive quarterly beats and attractive valuation metrics including a P/E of 14.98 and P/S of 0.88. Recent expansion of value-based care partnerships with Humana positions the company for continued growth in kidney care services.
The stock presents a compelling value opportunity with analyst consensus target of $235.67 offering 33% upside potential, though investors face risks from regulatory pressures and narrowing profit margins. Warren Buffett's significant ownership (45%) and institutional buying activity provide confidence, but the bearish technical outlook and mixed analyst ratings (43% Buy, 52% Hold) suggest cautious optimism is warranted.
Ferrari (RACE) trades at $386.39, down slightly by 0.03% today. The stock shows strong fundamentals with consistent earnings beats (Q4 2025: $2.49 vs. $2.44 expected, Q1 2026: $2.73 vs. $2.70 expected, Q2 2026: $2.99 vs. $2.83 expected) and robust profitability (net margin 22.25%, ROE 45.45%). Technical indicators are bearish overall, with the current price near support at $385. Recent news highlights a share buyback program and partnership with Rakuten effective January 2027.
Outlook: Analyst consensus is bullish with a $462.75 price target (73.69% buy ratings). Opportunities include strong brand equity, margin expansion, and strategic initiatives. Risks involve high valuation multiples (P/E 37.19, P/S 8.25), economic sensitivity, and execution of growth plans. The stock offers growth potential but requires monitoring of valuation and market conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Davita Inc
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →About Ferrari NV
Ferrari engineers and manufactures some of the world's most expensive exotic sports cars. The Ferrari brand is synonymous with Formula One racing, exclusivity, Italian design, and state-of-the-art technology. Ferrari also has a captive finance company that provides funding for dealers and clients.
Read more on RACE →
